View our Apixaban products

Apixaban Facts

  • Molecular mass: 460 D
  • Plasma half-life: 9-14h
  • Peak plasma time: 3-4 hours after oral administration
  • Bioavailability: 50%
  • Composition: C25H25N5O4 Clinical Aspects of Apixaban


Apixaban (Eliquis®) is a direct factor Xa inhibitor. Apixaban, like rivaroxaban, inhibits factor Xa directly, selectively and reversible as well as free as bound in the prothrombinase complex. The benefits of this drug are oral administration and well predictable pharmacokinetics and anticoagulation.

Factor Xa catalyzes the conversion of prothrombin to thrombin, the final enzyme in the coagulation cascade that is responsible for fibrin clot formation. Apixaban has no direct effect on platelet aggregation, but by inhibiting factor Xa, it indirectly decreases clot formation induced by thrombin.

If monitoring of anticoagulation therapy or an individual dose setting is necessary, a functional anti-factor Xa chromogenic assay (e.g. Chromogenix Coamatic® Heparin) should be used. In this assay, plasma spiked with Apixaban has to be used for generation of a standard curve.

Clinical or Research use of Apixaban

  • Prevention of venous thromboembolic events (VTE) in adult subjects who have undergone elective hip or knee replacement surgery
  • Prevention of stroke and systemic embolism in adult subjects with non-valvular atrial fibrillation (NVAF)
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults

View our Apixaban products

Search this site for Apixaban